Marinus Pharmaceuticals Announces PCDH19 Epilepsy Ganaxolone Phase 2 Clinical Trial

Marinus Pharmaceuticals has initiated a Phase 2 clinical study of ganaxolone as an adjunctive therapy for uncontrolled seizures in PCDH19 female pediatric epilepsy. Ganaxolone has been previously evaluated in multiple pediatric seizure disorders in children age 4 months through 15 years – with positive results on improving seizure frequencies. The most common adverse events across clinical trials are dizziness, fatigue and somnolence. 

Learn more about the Phase 2 study and ganaxolone here.